This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Doniger, J.
Right arrow Articles by Rosenthal, L. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Doniger, J.
Right arrow Articles by Rosenthal, L. J.

Next Article 

Clinical Microbiology Reviews, July 1999, p. 367-382, Vol. 12, No. 3
0893-8512/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Human Cytomegalovirus and Human Herpesvirus 6 Genes That Transform and Transactivate

Jay Doniger, Sumitra Muralidhar, and Leonard J. Rosenthal*

Department of Microbiology and Immunology, Georgetown University Medical Center, Washington, D.C. 20007

This review is an update on the transforming genes of human cytomegalovirus (HCMV) and human herpesvirus 6 (HHV-6). Both viruses have been implicated in the etiology of several human cancers. In particular, HCMV has been associated with cervical carcinoma and adenocarcinomas of the prostate and colon. In vitro transformation studies have established three HCMV morphologic transforming regions (mtr), i.e., mtrI, mtrII, and mtrIII. Of these, only mtrII (UL111A) is retained and expressed in both transformed and tumor-derived cells. The transforming and tumorigenic activities of the mtrII oncogene were localized to an open reading frame (ORF) encoding a 79-amino-acid (aa) protein. Furthermore, mtrII protein bound to the tumor suppressor protein p53 and inhibited its ability to transactivate a p53-responsive promoter. In additional studies, the HCMV immediate-early protein IE86 (IE2; UL122) was found to interact with cell cycle-regulatory proteins such as p53 and Rb. However, IE86 exhibited transforming activity in vitro only in cooperation with adenovirus E1A. HHV-6 is a T-cell-tropic virus associated with AIDS-related and other lymphoid malignancies. In vitro studies identified three transforming fragments, i.e., SalI-L, ZVB70, and ZVH14. Of these, only SalI-L (DR7) was retained in transformed and tumor-derived cells. The transforming and tumorigenic activities of SalI-L have been localized to a 357-aa ORF-1 protein. The ORF-1 protein was expressed in transformed cells and, like HCMV mtrII, bound to p53 and inhibited its ability to transactivate a p53-responsive promoter. HHV-6 has also been proposed to be a cofactor in AIDS because both HHV-6 and human immunodeficiency virus type 1 (HIV-1) have been demonstrated to coinfect human CD4+ T cells, causing accelerated cytopathic effects. Interestingly, like the transforming proteins of DNA tumor viruses such as simian virus 40 and adenovirus, ORF-1 was also a transactivator and specifically up-regulated the HIV-1 long terminal repeat when cotransfected into CD4+ T cells. Finally, based on the interactions of HCMV and HHV-6 transforming proteins with tumor suppressor proteins, a scheme is proposed for their role in oncogenesis.

* Corresponding author. Mailing address: Department of Microbiology and Immunology, Georgetown University Medical Center, 3900 Reservoir Rd. NW, Washington, DC 20007. Phone: (202) 687-1140. Fax: (202) 687-1264. E-mail: rosenthl{at}gunet.georgetown.edu.

Clinical Microbiology Reviews, July 1999, p. 367-382, Vol. 12, No. 3
0893-8512/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Maussang, D., Verzijl, D., van Walsum, M., Leurs, R., Holl, J., Pleskoff, O., Michel, D., van Dongen, G. A. M. S., Smit, M. J. (2006). Human cytomegalovirus-encoded chemokine receptor US28 promotes tumorigenesis. Proc. Natl. Acad. Sci. USA 103: 13068-13073 [Abstract] [Full Text]  
  • Erlach, K. C., Bohm, V., Seckert, C. K., Reddehase, M. J., Podlech, J. (2006). Lymphoma cell apoptosis in the liver induced by distant murine cytomegalovirus infection.. J. Virol. 80: 4801-4819 [Abstract] [Full Text]  
  • Ishii, H H, Gobe, G C, Yoneyama, J, Mukaide, M, Ebihara, Y (2004). Role of p53, apoptosis, and cell proliferation in early stage Epstein-Barr virus positive and negative gastric carcinomas. J. Clin. Pathol. 57: 1306-1311 [Abstract] [Full Text]  
  • Mauser, A., Saito, S.'i., Appella, E., Anderson, C. W., Seaman, W. T., Kenney, S. (2002). The Epstein-Barr Virus Immediate-Early Protein BZLF1 Regulates p53 Function through Multiple Mechanisms. J. Virol. 76: 12503-12512 [Abstract] [Full Text]  
  • Janelle, M.-E., Gravel, A., Gosselin, J., Tremblay, M. J., Flamand, L. (2002). Activation of Monocyte Cyclooxygenase-2 Gene Expression by Human Herpesvirus 6. ROLE FOR CYCLIC AMP-RESPONSIVE ELEMENT-BINDING PROTEIN AND ACTIVATOR PROTEIN-1. J. Biol. Chem. 277: 30665-30674 [Abstract] [Full Text]  
  • Cobbs, C. S., Harkins, L., Samanta, M., Gillespie, G. Y., Bharara, S., King, P. H., Nabors, L. B., Cobbs, C. G., Britt, W. J. (2002). Human Cytomegalovirus Infection and Expression in Human Malignant Glioma. Cancer Res. 62: 3347-3350 [Abstract] [Full Text]  
  • Kotenko, S. V., Saccani, S., Izotova, L. S., Mirochnitchenko, O. V., Pestka, S. (2000). Human cytomegalovirus harbors its own unique IL-10 homolog (cmvIL-10). Proc. Natl. Acad. Sci. USA 97: 1695-1700 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»